Updated Interim Results of Sonrotoclax + Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM): An All-Oral Treatment

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-09-01 DOI:10.1016/S2152-2650(25)03464-0

Binod Dhakal, Malin Hultcrantz, Nitya Nathwani, Christopher P. Venner, Jin Lu, Michael Slade, Jonathan L. Kaufman, Hun Chuah, Chang-Ki Min, Kihyun Kim, Huan Cheng, Adam Idoine, Wanhua Zhang, Xin Wang, Amit Agarwal, Hang Quach

引用次数: 0

查看原文本刊更多论文

Sonrotoclax +地塞米松治疗t（11;14）阳性复发/难治性多发性骨髓瘤（R/R MM）患者的最新中期结果：全口服治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.